Icon (NASDAQ:ICLR) Downgraded by Rothschild & Co Redburn to Hold

Rothschild & Co Redburn cut shares of Icon (NASDAQ:ICLR) from a buy rating to a hold rating in a report published on Tuesday morning, Marketbeat.com reports. Rothschild & Co Redburn currently has $100.00 price objective on the medical research company’s stock.

Other analysts also recently issued reports about the stock. BMO Capital Markets reissued a “market perform” rating and set a $100.00 target price on shares of Icon in a research note on Thursday, February 12th. Robert W. Baird set a $119.00 price objective on shares of Icon in a research note on Friday. Zacks Research upgraded Icon from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 25th. Mizuho set a $216.00 price objective on Icon in a research note on Friday, January 9th. Finally, Truist Financial reiterated a “hold” rating and set a $222.00 price target (down previously from $231.00) on shares of Icon in a report on Thursday, January 8th. Five investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $164.33.

Icon Stock Performance

Shares of ICLR opened at $88.62 on Tuesday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.06 and a current ratio of 1.06. The firm has a fifty day moving average of $172.29 and a 200-day moving average of $173.74. The company has a market cap of $7.16 billion, a price-to-earnings ratio of 11.99, a price-to-earnings-growth ratio of 1.96 and a beta of 1.27. Icon has a 1 year low of $66.57 and a 1 year high of $211.00.

Institutional Investors Weigh In On Icon

Several institutional investors and hedge funds have recently made changes to their positions in ICLR. Balyasny Asset Management L.P. acquired a new stake in shares of Icon during the 4th quarter worth about $13,763,000. Guggenheim Capital LLC bought a new stake in Icon during the fourth quarter worth about $244,000. AQR Capital Management LLC acquired a new stake in shares of Icon during the fourth quarter worth approximately $308,000. Harris Associates L P raised its stake in shares of Icon by 7.2% in the fourth quarter. Harris Associates L P now owns 2,510,166 shares of the medical research company’s stock valued at $457,402,000 after acquiring an additional 167,607 shares during the last quarter. Finally, Braidwell LP bought a new position in shares of Icon in the fourth quarter valued at approximately $13,369,000. Institutional investors and hedge funds own 95.61% of the company’s stock.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.